Janux Therapeutics, Inc. (JANX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US47103J1051
Janux Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 10.00 m USD |
| Operating income | -157.67 m USD |
| EBIT | -113.63 m USD |
| Net income | -113.63 m USD |
| Diluted EPS – continuing operations | -1.83 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Janux Therapeutics, Inc.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
More stocks
- Willdan Group, Inc. (WLDN)
- JPG (5323.KL)
- Capitol Federal Financial, Inc. (CFFN)
- Innovative Medical Management Co Ltd (002173.SZ)
- CNB FINANCIAL CORP/PA (CCNE)
- Compagnie des Alpes SA (CDA.PA)
- Aurisco Pharmaceutical Co Ltd (605116.SS)
- Zhongli Science and Technology Group Co Ltd (002309.SZ)
- Cpi Fim SA (OPG.WA)
- Brilliance China Automotive Holdings Ltd (1114.HK)
- Medincell SA (MEDCL.PA)
- Simply Good Foods Co (SMPL)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.